Statin use may reduce the risk of prostate cancer recurrence among men who have undergone a radical prostatectomy. These findings were recently published in the journal Cancer.
Active surveillance—sometimes referred to as “watchful waiting”—may be acceptable treatment for low-risk prostate cancer, according to the results of a study published early online in the Journal of the National Cancer Institute.
Jevtana® (cabazitaxel), a new chemotherapy drug, was approved for use in combination with prednisone for thetreatment of patients with metastatic hormone-refractory prostate cancer previously treated with a Taxotere® (docetaxel)-containing regimen.
